dc.contributor.author | Assemblée mondiale de la Santé, 49 | |
dc.date.accessioned | 2015-12-08T13:34:07Z | |
dc.date.available | 2015-12-08T13:34:07Z | |
dc.date.issued | 1996 | |
dc.identifier.govdoc | A49/A/Conf.Paper No.4 | |
dc.identifier.uri | https://iris.who.int/handle/10665/201168 | |
dc.description | Point 17 de l'ordre du jour | en_US |
dc.language.iso | fr | en_US |
dc.publisher | Organisation mondiale de la Santé | en_US |
dc.subject | Pharmaceutical products | en_US |
dc.subject.mesh | Pharmaceutical Preparations | en_US |
dc.subject.mesh | Quality Control | en_US |
dc.subject.mesh | Drugs, Essential | en_US |
dc.subject.mesh | Drug Delivery Systems | en_US |
dc.subject.mesh | Drug Industry | en_US |
dc.title | Stratégie pharmaceutique révisée : projet de résolution contenu dans la résolution EB97.R14 tel que modifié par un groupe de rédaction | en_US |
dc.type | Governing body documents | en_US |
dc.subject.meshqualifier | standards | en_US |